BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
Competitive Landscape Also Changing
Executive Summary
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.